|
|
| Line 1: |
Line 1: |
| | | * The optimal therapy for adult T-cell leukemia depends on the clinical variant of the disease. |
| | | * Chronic and smoldering adult T-cell leukemia patients are usually managed by either observation, skin directed therapies, or a combination of idovudine and interferon therapy. |
| ===prognosis===
| | * Acute adult T-cell leukemia patients are usually managed by either chemotherapy, supportive care, allogeneic stem cell transplant, or a combination of zidovudine and interferon therapy. |
| | | * Adult T-cell lymphoma patients are usually managed by either chemotherapy, supportive care, or allogeneic stem cell transplant. |
| | |
| * The table below lists prognostic factors for adult T-cell leukemia patients:<ref name="pmid20425378">{{cite journal| author=Mahieux R, Gessain A| title=Adult T-cell leukemia/lymphoma and HTLV-1. | journal=Curr Hematol Malig Rep | year= 2007 | volume= 2 | issue= 4 | pages= 257-64 | pmid=20425378 | doi=10.1007/s11899-007-0035-x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20425378 }} </ref><ref name="pmid18042693">{{cite journal| author=Matutes E| title=Adult T-cell leukaemia/lymphoma. | journal=J Clin Pathol | year= 2007 | volume= 60 | issue= 12 | pages= 1373-7 | pmid=18042693 | doi=10.1136/jcp.2007.052456 | pmc=PMC2095573 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18042693 }} </ref><ref name="pmid26361794">{{cite journal| author=Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y et al.| title=Treatment and survival among 1594 patients with ATL. | journal=Blood | year= 2015 | volume= 126 | issue= 24 | pages= 2570-7 | pmid=26361794 | doi=10.1182/blood-2015-03-632489 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26361794 }} </ref> | |
| | |
| {| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px"
| |
| |valign=top|
| |
| |+
| |
| ! style="background: #4479BA; width: 250px; color: #FFFFFF;"|'''Prognostic Factor'''
| |
| | |
| ! style="background: #4479BA; width: 600px; color: #FFFFFF;"|'''Description'''
| |
| | |
| |-
| |
| | |
| | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Clinical subtype'''|| style="padding: 5px 5px; background: #F5F5F5;" |
| |
| :* Acute and lymphomatous subtypes have a poor prognosis, where as chronic and smouldering subtypes have a good prognosis.
| |
| |-
| |
| | |
| | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Age'''|| style="padding: 5px 5px; background: #F5F5F5;"|
| |
| :* Males are associated with a worse prognosis when compared to females.
| |
| |-
| |
| | |
| | |
| | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Performance status'''|| style="padding: 5px 5px; background: #F5F5F5;"|
| |
| :* Patient's poor [[performance status]] is associated with a worse prognosis.
| |
| |-
| |
| | |
| | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Calcium level'''|| style="padding: 5px 5px; background: #F5F5F5;" |
| |
| :* Hypercalcemia is associated with a worse prognosis.
| |
| | |
| |-
| |
| | |
| | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Leukocyte count'''|| style="padding: 5px 5px; background: #F5F5F5;" |
| |
| :* An elevated leukocyte count is associated with a worse prognosis.
| |
| | |
| |-
| |
| | |
| | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Lactate dehydrogenase (LDH) level'''|| style="padding: 5px 5px; background: #F5F5F5;"|
| |
| :* Elevated level of [[LDH]] is associated with a worse prognosis.
| |
| | |
| |-
| |
| | |
| | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''β2-microglobulin level '''|| style="padding: 5px 5px; background: #F5F5F5;"|
| |
| :* An elevated β2-microglobulin level is associated with a worse prognosis.
| |
| | |
| |-
| |
| | |
| | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Lymphocyte surface markers'''|| style="padding: 5px 5px; background: #F5F5F5;"|
| |
| :* Over expression of [[CD25]] is associated with a worse prognosis.
| |
| |-
| |
| | |
| | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Neuron‐specific enolase'''|| style="padding: 5px 5px; background: #F5F5F5;"|
| |
| :* An elevated neuron‐specific enolase level is associated with a worse prognosis.
| |
| |}
| |